Complete financial analysis of CytoMed Therapeutics Limited (GDTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CytoMed Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Mega Uranium Ltd. (MGA.TO) Income Statement Analysis – Financial Results
- NetSol Technologies, Inc. (NTWK) Income Statement Analysis – Financial Results
- Patriot Transportation Holding, Inc. (PATI) Income Statement Analysis – Financial Results
- Reynolds Consumer Products Inc. (REYN) Income Statement Analysis – Financial Results
- Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Income Statement Analysis – Financial Results
CytoMed Therapeutics Limited (GDTC)
About CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 290.56K | 270.34K | 84.18K | 44.92K | 0.00 |
| Cost of Revenue | 77.47K | 6.48K | 2.59K | 3.50K | 0.00 |
| Gross Profit | 213.09K | 263.86K | 81.59K | 41.43K | 0.00 |
| Gross Profit Ratio | 73.34% | 97.60% | 96.92% | 92.22% | 0.00% |
| Research & Development | 1.20M | 1.13M | 806.45K | 784.20K | 323.98K |
| General & Administrative | 344.25K | 443.29K | 433.47K | 112.32K | 0.00 |
| Selling & Marketing | 25.24K | 0.00 | 1.83K | 4.67K | 0.00 |
| SG&A | 1.93M | 443.29K | 435.31K | 116.99K | 29.72K |
| Other Expenses | 0.00 | -195.32K | 36.13K | 47.81K | 0.00 |
| Operating Expenses | 3.12M | 1.38M | 1.28M | 949.00K | 451.04K |
| Cost & Expenses | 3.20M | 1.38M | 1.28M | 949.00K | 451.04K |
| Interest Income | 38.73K | 1.56K | 2.49K | 79.71K | 20.06K |
| Interest Expense | 0.00 | 92.99K | 87.03K | 79.71K | 0.00 |
| Depreciation & Amortization | 77.47K | 291.84K | 243.92K | 220.99K | 97.23K |
| EBITDA | -2.94M | -1.11M | -1.19M | -728.02K | -349.62K |
| EBITDA Ratio | -1,011.10% | -410.85% | -1,412.07% | -1,620.57% | 0.00% |
| Operating Income | -2.91M | -1.40M | -1.43M | -949.00K | -446.85K |
| Operating Income Ratio | -1,002.20% | -518.81% | -1,701.84% | -2,112.48% | 0.00% |
| Total Other Income/Expenses | -219.50K | -922.48K | -320.96K | -513.22K | -19.10K |
| Income Before Tax | -3.13M | -2.33M | -1.53M | -1.47M | -465.95K |
| Income Before Tax Ratio | -1,077.75% | -860.05% | -1,822.31% | -3,266.03% | 0.00% |
| Income Tax Expense | 373.69 | 1.22K | -53.43K | 84.71K | 0.00 |
| Net Income | -3.13M | -2.40M | -1.53M | -1.47M | -465.95K |
| Net Income Ratio | -1,077.85% | -887.02% | -1,822.31% | -3,266.03% | 0.00% |
| EPS | -0.29 | -0.30 | -0.22 | -0.25 | -0.08 |
| EPS Diluted | -0.29 | -0.30 | -0.22 | -0.25 | -0.08 |
| Weighted Avg Shares Out | 10.63M | 7.92M | 6.93M | 5.90M | 5.55M |
| Weighted Avg Shares Out (Dil) | 10.63M | 7.92M | 6.93M | 5.90M | 5.55M |
CytoMed Therapeutics: An Innovative Immunology Biotech Company To Watch
CytoMed Expands Research Collaboration into China After Entering Into MOU
CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γD T In Vivo Persistency
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
CytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell Technology
Why Is CytoMed Therapeutics (GDTC) Stock Up 157% Today?
U.S. IPO Weekly Recap: Small Deals Drive Activity In The IPO Market's Short Week
Source: https://incomestatements.info
Category: Stock Reports